2015 All-Japan Research Team: Health Care & Pharmaceuticals, No. 1: Hidekatsu Watanabe
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

2015 All-Japan Research Team: Health Care & Pharmaceuticals, No. 1: Hidekatsu Watanabe

2015-04-tom-johnson-all-japan-research-team-hidekatsu-watanabe.jpg

Hidekatsu Watanabe of Mizuho Securities Group holds on the top spot on this roster and captures third place on the OTC & Small Companies lineup.

< The 2015 All-Japan Research Team

2015-04-tom-johnson-all-japan-research-team-hidekatsu-watanabe.jpg

Hidekatsu Watanabe

Mizuho Securities Group

First-Place Appearances: 2


Total Appearances: 6


Analyst Debut: 2006


Hidekatsu Watanabe of Mizuho Securities Group holds on the top spot on this roster and captures third place on the OTC & Small Companies lineup. The 48-year-old analyst possesses “a very solid knowledge of the company managements, history and corporate cultures and knows how to combine this with a view — more often correct than not — on the share prices,” one portfolio manager declares. Watanabe is bullish on Japanese medical device makers that export their products, particularly to the U.S. For instance, he urges clients to buy Sysmex Corp., which develops clinical testing equipment, because he expects the Hyogo-headquartered manufacturer to increase its share of the U.S. hematology market even as it is seeing steady growth in emerging markets, including China. He is similarly upbeat on Aichi’s Asahi Intecc Co., deeming this provider likely to continue gaining global market share in its main angioplasty guidewire business. A third medical equipment maker that is increasing its exposure outside its domestic market is Terumo Corp. of Tokyo. Watanabe is forecasting that the company will return to double-digit profit growth this fiscal year, which ends in March 2016, citing rising use of its high-margin Ultimaster drug-eluting stent and overseas expansion for recently launched products with cardiac and vascular applications.



Gift this article